After making Forbes list for the next billion-dollar startup, anxious investors are hoping a Ginkgo Bioworks IPO is in the works.
That's because biotech and healthcare IPOs are netting investors gains as much as 300% so far in 2017.
by Jack Delaney
After making Forbes list for the next billion-dollar startup, anxious investors are hoping a Ginkgo Bioworks IPO is in the works.
That's because biotech and healthcare IPOs are netting investors gains as much as 300% so far in 2017.
by Jack Delaney
In recent IPO news, Wall Street is buzzing about a secretive company that could go public.
This biotech firm is valued by some at $4.7 billion, despite not having any products on the market.